1 completed, 1 recruiting, 1 terminated. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Crizotinib (Xalkori): new trials by email Literature Review of Crizotinib (Xalkori) trials Research Report on Crizotinib (Xalkori)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Darovasertib, Crizotinib (Xalkori) - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 450 | 2026-09-01 | 2026-09-15 |
| Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan) Crizotinib (Xalkori) - Non-small Cell Lung Cancer | Completed | Pfizer | 2029 | 2012-05-29 | 2019-09-13 | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer Crizotinib (Xalkori), Pazopanib, Pemetrexed - Advanced Cancers | Phase 1 | Terminated | M.D. Anderson Cancer Center | 178 | 2012-04-01 | 2021-09-13 |
Carcinoma, Non-Small-Cell Lung (1) · Uveal Melanoma (1)
IDEAYA Biosciences (1) · M.D. Anderson Cancer Center (1) · Pfizer (1)
United States (2) · Canada (1)